Say hello to SNAP™ Therapy.

The SNAP™ Therapy System combines the simplicity of advanced wound dressings with the proven benefits\(^1\) of negative pressure therapy in a discreet design that won’t get noticed.
SILENT: Allows patients to continue with activities of daily living

DISCREET: Pocket-sized, lightweight design can be hidden under clothes

CONVENIENT: Disposable, single-use components are available off-the-shelf for easy access

CLINICAL EVIDENCE

Armstrong
In a multicenter RCT, 132 patients with lower extremity diabetic and venous wounds were enrolled in the study. 118 patients were treated either with SNAP™ Therapy (n=59) or V.A.C.® Therapy (n=56), with 115 patients completing the study.

- Patients were treated for up to 16 weeks or complete wound closure.
- Primary end point analysis of wound size reduction found that SNAP™ Therapy treated subjects demonstrated non-inferiority to V.A.C.® Therapy subjects at 4, 8, 12 and 16 weeks (p=0.0030, 0.0130, 0.0051 and 0.0044, respectively).
- The study indicated that the effect of the SNAP™ Therapy System was not significantly different than that of the V.A.C.® Therapy System in promoting complete wound closure in the population studied (p=0.9620).
- SNAP™ Therapy patients reported less interruption of activities on daily living compared to V.A.C.® Therapy patients. However, pain associated with treatment was not significantly different between treatment groups.
- Other benefits noted by the authors were shorter time to dressing application and ease of use.
- However, despite randomization, the initial wound size was significantly greater in the V.A.C.® Therapy patients than in the SNAP™ Therapy patients (mean of 9.95cm² vs 5.37cm²; p=0.0093)

Marston
In a multicenter RCT, 40 patients with venous leg ulcers were treated either with SNAP™ Therapy (n=19) or V.A.C.® Therapy (n=21)

- Patients were evaluated for 16 weeks or complete wound closure.
- Primary end point analysis of wound size reduction found that SNAP™ Therapy treated subjects significantly greater wound size reduction than in V.A.C.® Therapy subjects at 4, 8, 12 and 16 weeks (p=0.0039, 0.0086, 0.0002, and 0.0005, respectively).
- 53% of SNAP™ Therapy patients achieved 50% wound closure at 30 days compared to 24% of V.A.C.® Therapy patients.
- However, despite randomization, the initial wound size was significantly greater in the V.A.C.® Therapy patients than in the SNAP™ Therapy patients (mean of 11.6cm² vs 4.49cm²).

To order product or for more information, call 800-275-4524 or visit acelity.com

REFERENCES